22 min
Episode 34: Are Nasal Polyps an Autoimmune Disease? allergytalk
-
- Health & Fitness
Originally Recorded 4/18/2023
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
Combined ICS/SBA Reduces Asthma Exacerbations
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
CRSwNP Patients have Impaired Sense of Smell and Taste
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials.
Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.
Anti-dsDNA IgG May Predict Nasal Polyp Recurrence
Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Joshi has the following disclosures:
Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent
Clinical trial funding: GlaxoSmithKline Sanofi
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Originally Recorded 4/18/2023
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
Combined ICS/SBA Reduces Asthma Exacerbations
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
CRSwNP Patients have Impaired Sense of Smell and Taste
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials.
Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.
Anti-dsDNA IgG May Predict Nasal Polyp Recurrence
Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Joshi has the following disclosures:
Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent
Clinical trial funding: GlaxoSmithKline Sanofi
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
22 min